References

Low-density lipoproteins cause atherosclerotic cardiovascular disease

10.1093/eurheartj/ehx144 · 2017 · External reference

Cholesterol Treatment trialists' (CTT) collaborators. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials

10.1016/s0140-6736(12)60367-5 · 2012 · External reference

Pitavastatin to prevent cardiovascular disease in HIV infection

10.1056/nejmoa2304146 · 2023 · External reference

Bempedoic acid for primary prevention of cardiovascular events in statin-intolerant patients

10.1001/jama.2023.9696 · 2023 · External reference

STAREE Investigators. Atorvastatin, cardiovascular events, and disability-free survival in older adults

10.1056/nejmoa2607314 · 2026 · External reference

VESALIUS-CV investigators. Evolocumab to reduce first major cardiovascular events in patients without known significant atherosclerosis and with diabetes

10.1001/jama.2026.3277 · 2026 · External reference

2025 Focused update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias

10.1093/eurheartj/ehaf190 · 2025 · External reference

2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia

10.1016/j.jacc.2025.11.016 · 2026 · External reference

Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials

10.1016/s0140-6736(18)31942-1 · 2019 · External reference

Evaluation of time to benefit of statins for the primary prevention of cardiovascular events in adults aged 50 to 75 years: a meta-analysis

10.1001/jamainternmed.2020.6084 · 2021 · External reference